Annie Guérin
 
                    Education
M.S. and B.S., economics, Université de Sherbrooke
Summary of Experience
Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes (PROs), safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.
- 
                                                        Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based StudyAmerican Journal of Ophthalmology. 2019 Feb;198:181-192 
 2024Dana R, Bradley JL, Guérin A, Pivneva I, Evans AM, Stillman IÖ 
- 
                                                        A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementiaJournal of Medical Economics, 2024 
 2024Grossberg G, Urganus A, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, Chan D, Guerin A, Aggarwal J 
- 
                                                        Patient journey of civilian adults diagnosed with posttraumatic stress disorder—A chart review studyCurrent Medical Research and Opinion, 2024 
 2024Davis LL, Urganus A, Gagnon-Sanschagrin P, Maitland J, Bedard J, Bellefleur R, Cloutier M, Guérin A, Aggarwal J 
- 
                                                        Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United StatesCurrent Medical Research and Opinion, 2024 
 2024Chiorean M, Jiang J, Candela N, Chen G, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, Guerin A, Fan T 
- 
                                                        Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn's Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE StudyAdvances in Therapy, 2024 
 2024Yarur A, Mantzaris GJ, Wang S, Adsul S, Kamble P, Cook E, Sajeev G, Guerin A, Bressler B 
- 
                                                        Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with DiarrheaAdvances in Therapy, 2024 
 2024Lacy B, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Bellefleur R, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre A 
- 
                                                        Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experimentJournal of Dermatological Treatment, 2024 
 2024Feldman SR, Guérin A, Gauthier-Loiselle M, Claxton AJ, Hazra NC, Meng Y, Gallant K, Balu S 
- 
                                                        Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational studyMedicine, 2024 
 2024Hari P, Latrémouille-Viau D, Lin P, Guérin A, Sasane M 
- 
                                                        Healthcare resource utilization and costs associated with psychiatric comorbidities in pediatric patients with attention-deficit/hyperactivity disorder: a claims-based case-cohort studyChild and Adolescent Psychiatry and Mental Health, 2024 
 2024Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Chen K, Chan D, Guerin A, Childress A 
- 
                                                        The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database studyJournal of Medical Economics, 2024 
 2024Gagnon-Sanschagrin P, Sanon M, Davidson M, Willey C, Kachroo S, Hoops T, Naessens D, Guerin A, Cloutier M 
- 
                                                        Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United StatesJournal of Health Economics Outcomes Research, 2023 
 2023Sharma P, Falk GW, Bhor M, Ozbay AB, Latrémouille-Viau D, Guérin A, Shi S, Elvekrog MM, Limburg P 
- 
                                                        Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United StatesMedicine, 2023 
 2023Sharma P, Falk GW, Bhor M, Ozbay AB, Latrémouille-Viau D, Guérin A, Shi S, Elvekrog MM, Limburg P 
- 
                                                        Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results from a Multi-Center International StudyClinical Lymphoma, Myeloma & Leukemia, 2023 
 2023Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR 
- 
                                                        Treatment Patterns among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims AnalysisAdvances in Therapy, 2023 
 2023Schein J, Childress A, Gagnon-Sanschagrin P, Maitland J, Bedard J, Cloutier M, Guérin A 
- 
                                                        Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States - a retrospective claims studyCurrent Medical Research and Opinion, 2023 
 2023Davis LL, Urganus A, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A, Aggarwal J 
- 
                                                        Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control studyBMC Psychiatry, 2023 
 2023Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Arpin E, Guerin A, Childress A 
- 
                                                        Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costsJournal of Medical Economics, 2023 
 2023Jesudian AB, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Chen J, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre AA 
- 
                                                        CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)Clinical Lymphoma, Myeloma & Leukemia, 2022 
 2022Kota V, Maegawa R, Latremouille-Viau D, Jadhav K, Rossi C, Guérin A, Lorga S 
- 
                                                        Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHDCurrent Medical Research and Opinion, 2022 
 2022Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A 
- 
                                                        Identifying Individuals with Undiagnosed Post-Traumatic Stress Disorder in a Large United States Civilian Population – A Machine Learning ApproachBMC Psychiatry, 2022 
 2022Gagnon-Sanschagrin P, Schein J, Urganis A, Serra E, Liang Y, Musingarimi P, Cloutier M, Guérin A, Davis L 
- 
                                                        Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United StatesJournal of Health Economics and Outcomes Research, 2022 
 2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P 
- 
                                                        Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial PerspectiveJournal of Health Economics and Outcomes Research, 2022 
 2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A 
- 
                                                        Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysisBMC Psychiatry, 2022 
 2022Schein J, Childress A, Adams J, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A 
- 
                                                        Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspectiveJournal of Medical Economics, 2022 
 2022Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Guerin A, Lefebvre P 
- 
                                                        The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab SequencesJournal of Clinical Pathways, 2022 
 2022Davids MS, Manzoor BS, Hazra NC, Fang H, Ravelo A, Han F, Guerin A, Sail K, Shapouri S, Shadman M 
- 
                                                        Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review studyBMC Psychiatry, 2022 
 2022Schein J, Childress A, Cloutier M, Desai U, Chin A, Simes M, Guerin A, Adams J 
- 
                                                        The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal PerspectiveThe Journal of Clinical Psychiatry, 2022 
 2022Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle CR 
- 
                                                        Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspectiveJournal of Managed Care & Specialty Pharmacy, 2022 
 2022Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P 
- 
                                                        Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency DepartmentAdvances in Therapy, 2022 
 2022Peacock WF, Slatkin N, Gagnon-Sanschagrin P, Maitland J, Guérin A, Joseph G 
- 
                                                        Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based SurveyKidney Medicine, 2022 
 2022Michalopoulos SN, Gauthier-Loiselle M, Aigbogun MS, Serra E, Bungay R, Clynes D, Cloutier M, Kahle E, Guérin A, Farag YMK, Wish JB 
- 
                                                        Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review StudyAdvances in Therapy, 2022 
 2022Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A 
- 
                                                        Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysisJournal of Medical Economics, 2021 
 2021Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X 
- 
                                                        Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United StatesJournal of Managed Care & Specialty Pharmacy, 2021 
 2021Blaiss MS, Meadows JA, Yu S, Robison DR, Hass SL, Norrett KE, Guerin A, Latremouille-Viau D, Tilles SA 
- 
                                                        Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updatesLeukemia & Lymphoma, 2021 
 2021Atallah EL, Sadek I, Maegawa R, Cao X, Latrémouille-Viau D, Pivneva I, Rossi C, Guérin A, Kota V 
- 
                                                        Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in JapanCardiology and Therapy, 2021 
 2021Chen L, Ionescu-Ittu R, Romdhani H, Guérin A, Kessler P, Borentain M, Friend K, DeSouza M, Sato N 
- 
                                                        Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims studyCurrent Medical Research and Opinion, 2021 
 2021Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Bungay R, Guérin A, Lefebvre P 
- 
                                                        Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United StatesJournal of Medical Economics, 2021 
 2021Volk ML, Burne R, Guérin A, Shi S, Joseph GJ, Heimanson Z, Ahmad M 
- 
                                                        Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysisLeukemia & Lymphoma, 2021 
 2021Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X 
- 
                                                        Prevalence of post-traumatic stress disorder in the United States: a systematic literature reviewCurrent Medical Research and Opinion, 2021 
 2021Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba C, Wang Y, King S, Levinson W, Guérin A, Lefebvre P, Davis LL 
- 
                                                        Health-care resource utilization associated with peanut allergy management under allergen avoidance among commercially insured individualsAllergy & Asthma Proceedings, 2021 
 2021Meadows JA, Yu S, Hass SL, Guerin A, Latremouille-Viau D, Tilles SA 
- 
                                                        Mental Health and Health-Related Quality of Life Among Nephrology Nurses: A Survey-Based Cross-Sectional StudyNephrology Nursing Journal, 2021 
 2021Montoya V, Donnini K, Gauthier-Loiselle M, Sanon M, Cloutier M, Maitland J, Guérin A, Dutka P, Pryor L, Thomas-Hawkins C, Voegel A, Hoffmann M, Savin S, Kurzman A, Kear T 
- 
                                                        Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspectiveJournal of Managed Care & Specialty Pharmacy, 2021 
 2021Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, Guérin A 
- 
                                                        Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stageJournal of Medical Economics, 2021 
 2021Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, Guérin A, Cloutier M 
- 
                                                        Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspectiveBMJ Open Opthalmology, 2021 
 2021Hariprasad SM, Joseph G, Gagnon-Sanschagrin P, Serra E, Bhattacharyya S, Bédard J, Guérin A, Albini TA 
- 
                                                        Impact of agitation in long-term care residents with dementia in the United StatesInternational Journal of Geriatric Psychiatry, 2021 
 2021Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G 
- 
                                                        Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitorsJournal of Medical Economics, 2021 
 2021
- 
                                                        The societal economic burden of autosomal dominant polycystic kidney disease in the United StatesBMC Health Services Research 
 2020Cloutier M, Manceur AM, Guerin A, Aigbogun MS, Oberdhan D, Gauthier-Loiselle M 
- 
                                                        In-hospital Therapy for Heart Failure with Reduced Ejection Fraction in the United StatesJournal of the American College of Cardiology: Heart Failure, 2020 
 2020Greene SJ, Triana TS, Ionescu-Ittu R, Burne RM, Guérin A, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L 
- 
                                                        Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart ReviewJournal of Alzheimer's Disease, 2020 
 2020Aigbogun MS, Cloutier M, Gauthier-Loiselle M, Guerin A, Ladouceur M, Baker RA, Grundman M, Duffy RA, Hartry A, Gwin K, Fillit H 
- 
                                                        Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payersJournal of Medical Economics, 2020 
 2020Shah NR, Bhor M, Latremouille-Viau D, Sharma VK, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Singh MK, Serra E, Davidson M, Xu L, Guerin A 
- 
                                                        Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndromeTherapeutic Advances in Gastroenterology, January 1, 2019 
 2019Lacy B, Ayyagari R, Guérin A, Lopez A, Shi S, Luo M 
- 
                                                        Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United StatesPharmacoEconomics. 2019 Feb;37(2):239-253 
 2019Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, Guérin A, Li N, Joseph G 
- 
                                                        Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health AdministrationEuropean Urology Oncology, 2019 
 2019Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thåström A, Liu S, Shi L, Leppert JT 
- 
                                                        Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspectiveLeukemia & Lymphoma, 2019 
 2019Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL 
- 
                                                        Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart reviewMelanoma Management, 2019 
 2019Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS 
- 
                                                        Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real worldJournal of Comparative Effectiveness Research, 2019 
 2019Ionescu-Ittu R, Shang A, Velde NV, Guerin A, Lin Y, Shi L, Shi S, Qayum N 
- 
                                                        Economic burden of relapse/recurrence in patients with major depressive disorderJournal of Drug Assessment, 2019 
 2019Gauthier G, Mucha L, Shi S, Guerin A 
- 
                                                        Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care SystemAmerican Journal of Ophthalmology, 2019 
 2019Dana R, Bradley JL, Guerin A, Pivneva I, Stillman IO, Evans AM, Schaumberg DA 
- 
                                                        Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1Advances in Therapy, 2019 
 2019Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM 
- 
                                                        Institutionalization risk and costs associated with agitation in Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2019 
 2019Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Aigbogun MS 
- 
                                                        Dry eye disease ranking among common reasons for seeking eye care in a large US claims databaseClinical Ophthalmology, 2019 
 2019Bradley JL, Stillman IO, Pivneva I, Guerin A, Evans AM, Dana R 
- 
                                                        Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancerJournal of Medical Economics. Mar 8 2018:1-15 
 2018Dalal AA, Guerin A, Mutebi A, Culver KW 
- 
                                                        Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based AnalysisJ Drugs Dermatol. Feb 1 2018;17(2):180-186 
 2018Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A, Ganguli A 
- 
                                                        Assessment of costs associated with adverse events in patients with cancerPloS One. 2018;13(4):e0196007 
 2018Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A 
- 
                                                        Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based AnalysisJ Drugs Dermatol. Feb 1 2018;17(2):187-194 
 2018Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guérin A, Ganguli A 
- 
                                                        Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational StudyAdvances in Therapy. 26 Mar 2018:1-12 
 2018Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T 
- 
                                                        Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapyLung Cancer. May 2018;119:112-119 
 2018Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R 
- 
                                                        Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal WomenAdvances in Therapy. Mar 20 2018 
 2018Gauthier G, Gagnon-Sanschagrin P, Guérin A, Burne R, Small T, Niravath P, Dalal AA 
- 
                                                        Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populationsJournal of Medical Economics. 2018 Jun;21(6):556-563 
 2018Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ 
- 
                                                        Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC)American Journal of Managed Care. Feb 19, 2018 
 2018Nellesen D, Dea K, Guerin A, Culver KW, Mutebi A, Dalal A 
- 
                                                        Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysisJ Drug Assess. 2018;7(1):21-27 
 2018Dalal AA, Guerin A, Mutebi A, Culver KW 
- 
                                                        The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort studyJournal of the American Academy of Dermatology. 2018 Jul;79(1):60-68 
 2018Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, Ganguli A 
- 
                                                        Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast CancerAdvances in Therapy. April 13, 2018 
 2018Dalal AA, Gagnon-Sanschagrin P, Burne R, Guérin A, Gauthier G, Small T, Niravath P 
- 
                                                        Assessing utility values for treatment-related health states of acute myeloid leukemia in the United StatesHealth and Quality of Life Outcomes. 2018 Sep 21;16(1):193 
 2018
- 
                                                        Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United StatesAdvances in Therapy, 2018 Oct;35(10):1671-1685 
 2018Seiter K, Latrémouille-Viau D, Guérin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ 
- 
                                                        The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data AnalysisDermatology and Therapy. 2018 Dec;8(4):557-569 
 2018Kimball AB, Sundaram M, Gauthier G, Guérin A, Pivneva I, Singh R, Ganguli A 
- 
                                                        Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast CancerAdvances in Therapy. 2018 Aug;35(8):1251-1264 
 2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA 
- 
                                                        Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast CancerAdvances in Therapy. 2018 Sep;35(9):1356-1367 
 2018Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guérin A, Niravath P, Small T 
- 
                                                        A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United StatesJournal of Medical Economics. 2018 Dec;21(12):1183-1190 
 2018Cloutier M, Greene M, Touya M, Gagnon-Sanschagrin P, Guérin A 
- 
                                                        Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based AnalysisJournal of Drugs in Dermatology, 2018 
 2018Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A 
- 
                                                        Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequencyJournal of Managed Care and Specialty Pharmacy. 2017;23(2):214-224 
 2017Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ 
- 
                                                        The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United StatesJournal of Medical Economics. Jan 2017;20(1):54-62 
 2017Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C. 
- 
                                                        Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United StatesJournal of Medical Economics. Jan 2017;20(1):63-71 
 2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L. 
- 
                                                        Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosisJournal of Medical Economics, 2017 October 
 2017
- 
                                                        Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review StudyAdvances in Therapy. May 2017;34(5):1145-1156 
 2017Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A 
- 
                                                        Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer PatientsAdvances in Therapy. Jul 2017;34(7):1673-1685 
 2017Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A 
- 
                                                        Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-AgonistsDrugs Real World Outcomes. Mar 2017;4(1):33-41 
 2017
- 
                                                        The economic burden of bipolar I disorder in the United States in 2015Journal of Affective Disorders. Jan 15 2018;226:45-51 
 2017Cloutier M, Greene M, Guerin A, Touya M, Wu E 
- 
                                                        Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in JapanJournal of Dermatological Treatment. Feb 2018;29(1):24-31 
 2017
- 
                                                        Overall survival in patients with glioblastoma before and after bevacizumab approvalCurrent Medical Research and Opinion. May 2018;34(5):813-820 
 2017Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm J 
- 
                                                        Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectJournal of Medical Economics, 2017 
 2017Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G 
- 
                                                        Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphomaLeukemia and Lymphoma. May 2018;59(5):1133-1142 
 2017Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L 
- 
                                                        Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexateJournal of the American Academy of Dermatology. Jan 2017;76(1):81-90 
 2017Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P 
- 
                                                        Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries with Chronic Myeloid LeukemiaJournal of Clinical Oncology. May 20 2017;35(15):1744-1745 
 2017Ritchie EK, Guerin A, Wolff J, Joseph G 
- 
                                                        Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysisBMC Psychiatry. Jun 19 2017;17(1):222 
 2017Gauthier G, Guérin A, Zhdanava M, Jacobson W, Nomikos G, Merikle E, François C, Perez V 
- 
                                                        The economic burden of common adverse events associated with metastatic colorectal cancer treatment (1)Journal of Medical Economics. Jan 2017;20(1):54-62 
 2017Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C 
- 
                                                        Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia(1)Journal of Medical Economics. Jan 2017;20(1):63-71 
 2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L 
- 
                                                        Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim studyJournal of Dermatological Treatment. Jun 2017;28(4):290-298 
 2017Wu JJ, Guérin A, Gauthier G, Sundaram M 
- 
                                                        Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment (1)Journal of Medical Economics. Oct 2017;20(10):1056-1065 
 2017
- 
                                                        The Economic Burden of Schizophrenia in the United States in 2013Journal of Clinical Psychiatry, June 2016;77(6):764-71 
 2016
- 
                                                        Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or ChemotherapyAdvances in Therapy, 2016 May 
 2016Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A 
- 
                                                        Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims studyExpert Opinion on Pharmacotherapy, 2016 04; 17(9): 1189-1196. e-pub ahead of print 2016/04/08 
 2016Guerin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. 
- 
                                                        Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claJournal of Medical Economics, 2016 19(4): 414-423 
 2016Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A. 
- 
                                                        Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective cCurrent Medical Research and Opinion, 2016 02; 32(2): 385-394 
 2016Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A. 
- 
                                                        Healthcare Resource Utilization, Healthcare Costs, and Dose Escalation in Psoriasis Patients Initiated on Ustekinumab versus Adalimumab: A Retrospective Claim StudyJournal of Dermatological Treatment, 2016 10: 1-23. doi: 10.1080/09546634.2016.1247946 
 2016Wu JJ, Guerin A, Gauthier G, Sundaram M 
- 
                                                        Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-linCurrent Medical Research and Opinion, 2016 32(5): 817-827. e-pub ahead of print 2016/01/09 
 2016Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L. 
- 
                                                        Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practiceSpringerPlus, 2016 03; 5: 395. e-pub ahead of print 2016/04/06 
 2016Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B 
- 
                                                        Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancerBreast Cancer Research and Treatment, 2016 05; 157(1): 145-156. e-pub ahead of print 2016/04/25 
 2016Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B 
- 
                                                        Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world settingCancer Med. 2015 May 20. doi: 10.1002/cam4.475. [Epub ahead of print] 
 2015Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM 
- 
                                                        ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancerCancer Epidemiol. 2015 Jun;39(3):307-12 
 2015Guerin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H 
- 
                                                        Psoriasis and risk of diabetes-associated microvascular and macrovascular complicationsJ Am Acad Dermatol. 2015 Jun;72(6):968-977.e2 
 2015Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P 
- 
                                                        Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medicationsJ Med Econ. 2013 Nov;16(11):1275-89 
 2015Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH 
- 
                                                        The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapyJ Med Econ. 2015 Mar;18(3):241-8 
 2015
- 
                                                        Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review studyCurrent Medical Research and Opinion. 2015 
 2015Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R 
- 
                                                        Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort studyLung Cancer. 2014 Dec;86(3):350-7 
 2014Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S 
- 
                                                        Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world settingOncologist. 2014 Sep;19(9):901-8 
 2014Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D 
- 
                                                        The impact of moderate-to-severe Crohn's Disease on employees' salary growthInflamm Bowel Dis. 2014 Oct;20(10):1734-8 
 2014Loftus EV Jr, Skup M, Ozbay AB, Wu E, Guerin A, Chao J, Mulani P 
- 
                                                        Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemiaCurr Med Res Opin. 2014 Nov;30(11):2317-28 
 2014Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ 
- 
                                                        Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysisJ Med Econ. 2014 Sep;17(9):646-57 
 2014Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ 
- 
                                                        Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipationAliment Pharmacol Ther. 2014 Jul;40(1):83-92 
 2014Guerin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ 
- 
                                                        Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phaseCurr Med Res Opin. 2014 Jul;30(7):1345-52 
 2014
- 
                                                        Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemiaJ Med Econ. 2014 Feb;17(2):89-98 
 2014
- 
                                                        Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysisSpringerplus. 2014 May 8;3:236 
 2014Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG 
- 
                                                        Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approachJ Gastrointest Cancer. 2014 Dec;45(4):431-40 
 2014Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ 
- 
                                                        Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysisClinical Lymphoma, Myeloma & Leukemia, 2014 
 2014DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ 
- 
                                                        Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinibCurr Med Res Opin. 2013 Sep;29(9):1075-82 
 2013Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ 
- 
                                                        A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosusJ Med Econ. 2013;16(6):793-800 
 2013Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C 
- 
                                                        Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approachJ Gastrointest Cancer. 2013 Jun;44(2):190-8 
 2013Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ 
- 
                                                        Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapyInt J Cardiol. 2013 Jul 31;167(2):564-9 
 2013Guerin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS 
- 
                                                        Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth andJ Med Econ. 2013 Oct;16(10):1203-15 
 2013Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH 
- 
                                                        Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysisJ Med Econ. 2013 Jul;16(7):962-75 
 2013Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH 
- 
                                                        Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysisCurrent Medical Research and Opinion, 2013 
 2013Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ 
- 
                                                        Risks of developing psychiatric disorders in pediatric patients with psoriasisJ Am Acad Dermatol. 2012 Jan 11. 
 2012Kimball A, Wu EQ, Guérin A, Yu AP, Tsaneva M, Gupta S, Bao Y, Mulani P 
- 
                                                        Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy2012 Nov;19(6):e157-66 
 2012Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M 
- 
                                                        Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancersJournal of Medical Economics, 1-30, November 27, 2012 
 2012Ray S, Bonthapally V, Holen K, Gauthier G, Wu EQ, Cloutier M, Guérin A 
- 
                                                        Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapyEuropean Journal of Paediatric Neurology, September 2012, Vol. 16, No. 5 
 2012Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E 
- 
                                                        Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-Br J Dermatol. 2012 Dec; 167(6):1374-81 
 2012Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM 
- 
                                                        Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysisCurrent Medical Research and Opinion, 2012 
 2012Chen L, Guérin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E 
- 
                                                        Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbiditiesAm J Clin Dermatol. 2011 Feb 1;12(1):51-62 
 2011Kimball A, Bensimon A, Guerin A, Yu AP, Wu EQ, Okun M, Bao Y, Gupta S, Mulani P 
- 
                                                        Economic burden of comorbidities in patients with psoriasis is substantialJ Eur Acad Dermatol Venereol. 2011 Feb; 25(2):157-63. Epub 2010 Jun 17. 
 2011Kimball A, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta S, Bao Y, Mulani P 
- 
                                                        Mortality and Nonadherence to AEDSSudden Unexpected Death in Epilepsy: Continuing the Global Conversation (Epilepsy Australia, Epilepsy Bereaved, and SUDEP Aware/North America, 2011) 
 2011Duh MS, Greenberg PE, Guerin A, Korves C 
- 
                                                        Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trialEur J Cancer. 2011 Jun 18. 
 2011Cella D, Pickard A, Duh MS, Guerin A, Mishagina N, Antras L, Neary M, McCann L, Hodge R, Sternberg CN 
- 
                                                        Increased risks of developing anxiety and depression in young patients with Crohn's diseaseAm J Gastroenterol. 2011 Sep;106(9):1670-7. doi: 10.1038/ajg.2011.142. Epub 2011 May 3. 
 2011Loftus E Jr, Guerin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani P 
- 
                                                        Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsyEpilepsy Behav. 2011 Oct;22(2):370-5. 
 2011Helmers S, Duh MS, Guerin A, Sarda S, Samuelson T, Bunker M, Olin B, Jackson S, Faught E 
- 
                                                        Clinical and economic outcomes of multiple versus single long-acting inhalers in COPDRespir Med. 2011 Dec;105(12):1861-71. Epub 2011 Jul 31. 
 2011Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J 
- 
                                                        Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalersJ Med Econ. 2011;14(4):486-96. Epub 2011 Jun 16. 
 2011Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J 
- 
                                                        Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French health dataAnn Pharmacother. 2011 Feb 8. 
 2011Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P 
- 
                                                        Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysisAm J Med. 2010 Apr;123(4):350-7 
 2010Kimball A, Guerin A, Latremouille-Viau D, Yu A, Gupta S, Bao Y, Mulani P 
- 
                                                        High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasisDermatology. 2010;220(2):128-37. Epub 2010 Feb 3 
 2010Saurat J, Guerin A, Yu A, Latremouille-Viau D, Wu E, Gupta S, Bao Y, Mulani P 
- 
                                                        Perceptions and prescribing considerations among US psychiatrists regarding drug–drug interactions associated with oral atypical antipsychoticsCurrent Medical Research and Opinion 2010, Pages 2735-2744. Published online 11/01/2010; doi:10.1185/03007995.2010.530159 
 2010Frois C, Guerin A, Saraogi A, Panish J, Dirani R 
- 
                                                        Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemiaCurrent Medical and Research Opinion, December 2010, Vol. 26, No. 12 , Pages 2861-2869 
 2010
- 
                                                        
- 
                                                        May 8, 2023
- 
                                                        May 31, 2024
- 
                                                    August 27, 2024
- 
                                                    June 14, 2024
- 
                                                    June 4, 2024
- 
                                                    February 26, 2024
- 
                                                    December 1, 2023
- 
                                                    October 23, 2023
- 
                                                    July 6, 2023
- 
                                                    March 22, 2023
- 
                                                    December 7, 2022
- 
                                                    October 17, 2022
- 
                                                    April 13, 2021
 
         
                                 
                                